N Novartis
Swiss multinational pharmaceutical corporation
Updates & Highlights
Yahoo Finance · about 14 hours ago
Novartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform
Yahoo Finance · about 17 hours ago
Novartis (SWX:NOVN) Could Be 9% Below Fair Value As Cosentyx Progress Lifts The Case
The National Law Review · about 23 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Novartis AG (NVS) And Encourages Investors to Connect
Recent Openings
View all 2 jobs arrow_forwardAll Jobs
Culture & Mission
Benefits & Perks
Equity/Stock Options
Ownership in the company
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
Generous PTO
Paid time off
401(k) Match
Retirement savings
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Novartis?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company arrow_forwardNews & Press
20 recentNovartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform
Novartis (SWX:NOVN) Takes Full Control Of A Brain Delivery Platform
Yahoo Finance · about 14 hours ago
Novartis (SWX:NOVN) Could Be 9% Below Fair Value As Cosentyx Progress Lifts The Case
Novartis (SWX:NOVN) Could Be 9% Below Fair Value As Cosentyx Progress Lifts The Case
Yahoo Finance · about 17 hours ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Novartis AG (NVS) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Novartis AG (NVS) And Encourages Investors to Connect
The National Law Review · about 23 hours ago
Novartis M&A Strategy Not So Bad As Claimed?
Novartis M&A Strategy Not So Bad As Claimed?
insights.citeline.com · 1 day ago
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
Chutes & Ladders—Legend poaches Novartis vet to boost commercial potential
Fierce Biotech · 1 day ago
Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
Novartis (NVS) Suffers its Third Drug Trial Setback in a Week, and its Worst Trading Day in Years
Yahoo Finance · 1 day ago
Why Is Novartis Stock Trading Higher Today? - Novartis (NYSE:NVS)
Why Is Novartis Stock Trading Higher Today? - Novartis (NYSE:NVS)
Benzinga · 2 days ago
After Novartis’ devastating M&A losses, long live the executive willing to try
After Novartis’ devastating M&A losses, long live the executive willing to try
BioSpace · 2 days ago
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
Novartis drops $125M for Sironax’s tech to cross blood-brain barrier
BioSpace · 2 days ago
Novartis abandons ALS antibody as TREM2 target disappoints again
Novartis abandons ALS antibody as TREM2 target disappoints again
The Pharma Letter · 2 days ago
Amgen Confident In Cardiometabolic Pipeline After Novartis’s Negative Lp(a) Readout
Amgen Confident In Cardiometabolic Pipeline After Novartis’s Negative Lp(a) Readout
insights.citeline.com · 3 days ago
Novartis acquires Sironax's brain delivery tech
Novartis acquires Sironax's brain delivery tech
FirstWord PHARMA · 3 days ago
Novartis halts ALS drug development after mid-stage trial failure
Novartis halts ALS drug development after mid-stage trial failure
Reuters · 3 days ago
Novartis to pay $125M for blood-brain barrier crossing platform
Novartis to pay $125M for blood-brain barrier crossing platform
biopharmadive.com · 3 days ago
Novartis Suffers Another Setback After Stock-Rocking Failures
Novartis Suffers Another Setback After Stock-Rocking Failures
Investor's Business Daily · 3 days ago
Top-20 Novartis shareholder demands board shake-up after back-to-back trial failures
Top-20 Novartis shareholder demands board shake-up after back-to-back trial failures
The Pharma Letter · 3 days ago
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
Novartis Gains a Way to Get Drugs Into the Brain, Buying Sironax Tech for $125M
MedCity News · 3 days ago
Novartis ends TREM2-targeting drug in ALS after study fail
Novartis ends TREM2-targeting drug in ALS after study fail
FirstWord Pharma · 3 days ago
Bronstein, Gewirtz & Grossman, LLC Encourages Novartis AG (NVS) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Novartis AG (NVS) Investors to Inquire about Securities Investigation
The National Law Review · 3 days ago
Novartis US Invests in Data and AI Capabilities for 6,000 Employees
Novartis US Invests in Data and AI Capabilities for 6,000 Employees
Novartis · 3 days ago